Skip to main content
HCPCS J1559 · Level II · Part B drug

J1559: immune globulin (Hizentra), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1559

Billing unit
100 MG
Hizentra injection
ASP payment limit
$14.786
October 2026; -0.7% vs July 2026
Practitioner MUE
2400
MAI 3
OPPS status
SI K
APC 1312
NCCI exposure
no PTP pairs
Coverage articles
2
8 states

TL;DR

HCPCS J1559 is the Level II code for Injection, immune globulin (hizentra), 100 mg, billed per 100 MG. The Medicare Part B ASP payment limit for October 2026 is $14.786 per billing unit, down 0.7% from July 2026. The practitioner MUE allows up to 2400 units per date of service (MAI 3), so a full 2400-unit day is $35,486.40 at the current limit. Under OPPS it carries status indicator K in APC 1312. J1559 is billed in units of 100 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names immune globulin: J1558 (Xembify from Grifols USA, LLC); J1555 (Cuvitru from Takeda Pharmaceuticals America, Inc); J1553 (Yimmugo from Kedrion Biopharma Inc); J1551 (Cutaquig); J1577 (Qivigy from Kedrion Biopharma Inc); J1557 (Gammaplex from Bio Products Laboratory; intravenous route; non-lyophilized; billed per 500 mg). The ASP crosswalk maps 8 NDCs to it, sold as Hizentra by CSL Behring L.L.C. 2 Medicare coverage articles list the code across 5 states plus DC and 2 territories, including A56786.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1559 at $14.786 per 100 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $14.883 in July 2026. Beneficiary coinsurance is 19%.

ASP payment limits for J1559
QuarterPayment limitPerCoinsurance
October 2026$14.786100 MG19%
July 2026$14.883100 MG—
CMS note: Inflation-adjusted coinsurance

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 8 NDCs from 1 labeler to J1559. Report the NDC in the claim's drug segment and bill the number of J1559 units that equals the quantity administered divided by 100 MG; the last column gives units per full package.

NDCs that crosswalk to J1559
NDCDrug nameLabelerPackage sizeBilling units / package
44206-0451-01HizentraCSL Behring L.L.C.5 × 110
44206-0452-02HizentraCSL Behring L.L.C.10 × 120
44206-0454-04HizentraCSL Behring L.L.C.20 × 140
44206-0455-10HizentraCSL Behring L.L.C.50 × 1100
44206-0455-25HizentraCSL Behring L.L.C.50 × 1100
44206-0456-21HizentraCSL Behring L.L.C.5 × 110
44206-0457-22HizentraCSL Behring L.L.C.10 × 120
44206-0458-24HizentraCSL Behring L.L.C.20 × 140

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J1559. For practitioners the limit is 2400 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1559 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services24003 Date of Service Edit: ClinicalCMS Policy
Facility outpatient hospital24003 Date of Service Edit: ClinicalCMS Policy
DME supplier24003 Date of Service Edit: ClinicalCMS Policy

MUE for J1559 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1559 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1559 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1559 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

2 current Medicare Administrative Contractor articles list J1559 in their HCPCS tables, covering 8 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J1559
ArticleTitleContractor(s)StatesRelated LCD
A56786Billing and Coding: Immune GlobulinNovitas Solutions, Inc.DC DE MD NJ PAL35093
A57778Billing and Coding: Immune GlobulinFirst Coast Service Options, Inc.FL PR VIL34007

Diagnoses Medicare contractors cover for J1559

2 billing and coding articles attach a covered diagnosis list to J1559: 30 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J1559
ICD-10-CMDescription (FY2027)Articles covering
D80.0Hereditary hypogammaglobulinemia2 of 2
D80.1Nonfamilial hypogammaglobulinemia2 of 2
D80.2Selective deficiency of immunoglobulin A [IgA]2 of 2
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses2 of 2
D80.4Selective deficiency of immunoglobulin M [IgM]2 of 2
D80.5Immunodeficiency with increased immunoglobulin M [IgM]2 of 2
D80.6Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia2 of 2
D80.7Transient hypogammaglobulinemia of infancy2 of 2
D80.8Other immunodeficiencies with predominantly antibody defects2 of 2
D81.0Severe combined immunodeficiency [SCID] with reticular dysgenesis2 of 2
D81.1Severe combined immunodeficiency [SCID] with low T- and B-cell numbers2 of 2
D81.2Severe combined immunodeficiency [SCID] with low or normal B-cell numbers2 of 2
D81.31Severe combined immunodeficiency due to adenosine deaminase deficiency2 of 2
D81.4Nezelof's syndrome2 of 2
D81.5Purine nucleoside phosphorylase [PNP] deficiency2 of 2
15 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1559 are counted here: a group whose instructions name J1559, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J1559, by article
ArticleContractorGroups that applyCovered codes for J1559Full list
A56786Novitas Solutions, Inc.group 2 applies to J155930On LCD L35093
A57778First Coast Service Options, Inc.group 2 applies to J155930On LCD L34007

Local coverage policies that list J1559

3 active Local Coverage Determinations list J1559 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1559 carries status indicator K and is assigned to APC 1312, with a published national unadjusted payment of $14.786. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1559 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $14.79 per 100 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J1559 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1559

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1559

What does HCPCS code J1559 describe?

J1559 is defined by CMS as "Injection, immune globulin (hizentra), 100 mg". Each billing unit represents 100 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1559 a CPT code?

No. J1559 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as immune globulin (Hizentra); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1559 reports the drug itself in 100 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1559 in October 2026?

The ASP-based payment limit is $14.786 per 100 MG, with 19% beneficiary coinsurance. The July 2026 limit was $14.883. Commercial payers use their own fee schedules.

How many units of J1559 can be billed per day?

The practitioner Medically Unlikely Edit is 2400 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "CMS Policy" as the rationale.

Which NDCs map to J1559?

The October 2026 ASP crosswalk lists 8 NDCs from 1 labeler: Hizentra (CSL Behring L.L.C.). For example NDC 44206-0451-01 (package size 5) equals 10 billing units of J1559.

Does J1559 have NCCI bundling edits?

No active practitioner PTP pairs list J1559 as a column-1 or column-2 code in the v323r0 release.

J1559 vs J1558: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1558 apart: Xembify from Grifols USA, LLC. J1559 is billed per 100 mg, limit $14.786, MUE 2400; J1558 is billed per 100 mg, limit $15.20, MUE 480. Report the code whose descriptor matches the product and setting in the record.

J1559 vs J1555: what is the difference?

Both are HCPCS Level II codes whose descriptor names immune globulin. What sets J1555 apart: Cuvitru from Takeda Pharmaceuticals America, Inc. J1559 is billed per 100 mg, limit $14.786, MUE 2400; J1555 is billed per 100 mg, limit $17.994, MUE 480. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J1559?

2 current Billing and Coding Articles in the Medicare Coverage Database list J1559, covering 5 states plus DC and 2 territories: A56786 (Billing and Coding: Immune Globulin); A57778 (Billing and Coding: Immune Globulin).

What diagnosis codes support J1559?

2 Medicare billing and coding articles list 30 covered ICD-10-CM codes for J1559 between them, for example D80.0 (Hereditary hypogammaglobulinemia); D80.1 (Nonfamilial hypogammaglobulinemia); D80.2 (Selective deficiency of immunoglobulin A [IgA]); D80.3 (Selective deficiency of immunoglobulin G [IgG] subclasses); D80.4 (Selective deficiency of immunoglobulin M [IgM]). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.